Ventyx Biosciences (VTYX) News
Market Cap: $84.29M
Avg Volume: 1.26M
Industry: Biotechnology
Sector: Healthcare
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 biomarker study in patients with early Parkinson's disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported fourth quarter and full year 2024 financial results and highlighted recent pipeline and business progress. “Heading into 2025, Ventyx has established itself as the leader in the field of NLRP3 inhibition having progressed two novel inhibitors, VTX3232 and VTX2735, into Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications.
globenewswire.com
Read More
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn's disease will be presented during the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) being held in Berlin, Germany from February 19-22, 2025. “The Phase 2 data for VTX958 in Crohn's disease represent an important milestone for TYK2 inhibition in inflammatory bowel disease,” said Raju Mohan, PhD, Founder and Chief Executive Officer.
globenewswire.com
Read More
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
globenewswire.com
Read More
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio
First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025
globenewswire.com
Read More
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company.
globenewswire.com
Read More
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
globenewswire.com
Read More
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials, I see obvious potential for Ventyx to outperform the market. Despite past troubles, management actions are addressing issues, though risks include volatility and the risk that drugs will not go commercial.
seekingalpha.com
Read More
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.
zacks.com
Read More
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.
benzinga.com
Read More
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease.
globenewswire.com
Read More
Ventyx Biosciences Announces Departure of Chief Financial Officer
SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company's SVP of Finance, has assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer for SEC reporting purposes. The company has initiated a search for a CFO.
globenewswire.com
Read More
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
globenewswire.com
Read More
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024
globenewswire.com
Read More
Dow Edges Lower; Ventyx Biosciences Shares Plummet
U.S. stocks were mostly higher toward the end of trading, while the Dow Jones index traded slightly lower on Monday.
benzinga.com
Read More
Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further
Ventyx Biosciences Inc VTYX stock is trading lower on Monday.
benzinga.com
Read More
VENTYX SHAREHOLDER ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Notified to Contact the Firm for Details
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
accesswire.com
Read More
VENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
globenewswire.com
Read More
VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
accesswire.com
Read More
VENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
globenewswire.com
Read More
VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details
NEW YORK, NY / ACCESSWIRE / June 21, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (NASDAQ:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
accesswire.com
Read More
VENTYX SHAREHOLDER ALERT: BFA Law is Investigating the Ventyx (Nasdaq:VTYX) Board for Trading on Inside Information to Avoid Losses, Contact the Firm for Details
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
accesswire.com
Read More
VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to submit your information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation . Why is Ventyx Being Investigated by BFA?
globenewswire.com
Read More
VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses
NEW YORK, NY / ACCESSWIRE / June 19, 2024 / If you are a shareholder of Ventyx Biosciences (NASDAQ:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
accesswire.com
Read More
VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
accesswire.com
Read More
VENTYX INSIDER TRADING ALERT: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses
NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to submit your information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation . Why is Ventyx Being Investigated by BFA?
globenewswire.com
Read More
VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
accesswire.com
Read More
VENTYX INVESTOR ALERT: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
accesswire.com
Read More
BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
accesswire.com
Read More
VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
globenewswire.com
Read More
STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
accesswire.com
Read More
VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
accesswire.com
Read More
VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
globenewswire.com
Read More
VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors
NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below.
globenewswire.com
Read More
VENTYX STOCK DROP ALERT: Ventyx (Nasdaq:VTYX) Directors Being Investigated for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact BFA Law About Your Rights
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / If you are a shareholder of Ventyx Biosciences (NASDAQ:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
accesswire.com
Read More
BREAKING VENTYX ALERT: Ventyx (Nasdaq: VTYX) Stock Declines 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below.
globenewswire.com
Read More
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice
globenewswire.com
Read More
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer.
globenewswire.com
Read More
Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript
Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Martin Auster - Chief Financial Officer Raju Mohan - Founder and Chief Executive Officer John Nuss - Chief Scientific Officer Conference Call Participants Liam Hiester - Piper Sandler Emily Bodnar - H.C. Wainwright Gospel Enyindah-Asonye - Morgan Stanley Alex Thompson - Stifel Derek Archila - Wells Fargo Sam Slutsky - Life Science Operator Good afternoon, ladies and gentlemen and welcome to the Ventyx Biosciences First Quarter 2024 Earnings Conference Call.
seekingalpha.com
Read More
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.
globenewswire.com
Read More
April 30, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTYX
NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77625&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
VTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX
NEW YORK , April 30, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's October 21, 2021 initial public offering (the "IPO" or "Offering"); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the "Class Period"), of the important April 30, 2024 lead plaintiff deadline. SO WHAT: If you purchased Ventyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
prnewswire.com
Read More
What Makes Ventyx Biosciences (VTYX) a New Buy Stock
Ventyx Biosciences (VTYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Read More
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77617&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77602&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX
NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77589&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 30, 2024.
accesswire.com
Read More
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc. (VTYX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77572&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Lawsuit - VTYX
NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77569&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 30, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) investors who purchased: (a) common stock pursuant and/or traceable to the Company's October 2021 initial public offering (“IPO”); and/or (b) securities between October 21, 2021 and November 6, 2023, inclusive (the “.
businesswire.com
Read More
Levi & Korsinsky Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
NEW YORK, NY / ACCESSWIRE / April 29, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77523&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
VTYX DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX
NEW YORK, April 29, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's October 21, 2021 initial public offering (the "IPO" or "Offering"); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the "Class Period"), of the important April 30, 2024 lead plaintiff deadline. SO WHAT: If you purchased Ventyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
prnewswire.com
Read More
Contact Levi & Korsinsky by April 30, 2024 Deadline to Join Class Action Against Ventyx Biosciences, Inc.(VTYX)
NEW YORK, NY / ACCESSWIRE / April 28, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77423&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 30, 2024.
accesswire.com
Read More
VTYX LAWSUIT ALERT: Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / April 28, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77407&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 30, 2024.
accesswire.com
Read More
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) and certain officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 24-cv-00415, is on behalf of all persons and entities other than Defendants who purchased or otherwise acquired: (a) Ventyx common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about October 21, 2021 (the "IPO" or "Offering"); and/or (b) Ventyx securities between October 21, 2021 and November 6, 2023, both dates inclusive (the "Class Period").
prnewswire.com
Read More
Levi & Korsinsky Reminds Ventyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
NEW YORK, NY / ACCESSWIRE / April 28, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77332&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
NEW YORK, NY / ACCESSWIRE / April 28, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77318&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Ventyx Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
NEW YORK, NY / ACCESSWIRE / April 28, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77305&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Investors in Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
NEW YORK, NY / ACCESSWIRE / April 26, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77137&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
NEW YORK , April 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ventyx Biosciences, Inc. (NASDAQ: VTYX). Shareholders who purchased shares of VTYX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
prnewswire.com
Read More
Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VTYX
NEW YORK, NY / ACCESSWIRE / April 26, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77122&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VTYX
NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77028&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences
NEW YORK , April 25, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) and reminds investors of the April 30, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ventyx To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in (a) Ventyx common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about October 21, 2021 (the "IPO" or "Offering"); and/or (b) Ventyx securities between October 21, 2021 and November 6, 2023, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
prnewswire.com
Read More
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX) - April 30, 2024 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77010&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Shareholders of Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=76860&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=76821&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Ventyx Biosciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX
NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=76810&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES , April 23, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ: VTYX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the ''Class Period''), are encouraged to contact the firm before April 30, 2024.
prnewswire.com
Read More
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 30, 2024.
accesswire.com
Read More
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / April 23, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=76739&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit
LOS ANGELES , April 23, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX). Class Period: October 21, 2021 – November 6, 2023 Lead Plaintiff Deadline: April 30, 2024 If you wish to serve as lead plaintiff of the Ventyx lawsuit, you can submit your contact information at www.glancylaw.com/cases/Ventyx-Biosciences-Inc/.
prnewswire.com
Read More
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 30, 2024.
accesswire.com
Read More
Ventyx Biosciences, Inc. Class Action: Levi & Korsinsky Reminds Ventyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
NEW YORK, NY / ACCESSWIRE / April 22, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=76472&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class Action - VTYX
NEW YORK, NY / ACCESSWIRE / April 21, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=76434&wire=1 or contact Joseph E. Levi, Esq.
accesswire.com
Read More